JONEL ALECCIA

Jonel Aleccia is a senior correspondent focused on health and safety for Kaiser Health News. She is a veteran health journalist with more than a decade of experience covering the intersection of health and public policy. Aleccia’s work has appeared in The New York Times, The Washington Post, NBC News and USA Today.

Biography:  https://khn.org/news/author/jonel-aleccia/

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

Salmonella Outbreak Linked to Cantaloupes Results in Eight Deaths Across US and Canada

Broke On: Thursday, 07 December 2023 A salmonella outbreak linked to cantaloupes has resulted in eight deaths and hundreds of illnesses across the United States and Canada. The outbreak has been particularly severe among the elderly and children, with more than half of the cases resulting in hospitalization. The recall was initiated by Cut Fruit Express and TGD Cuts, LLC, affecting various stores and brands.

Obesity Drug Wegovy Shows Potential in Reducing Heart Disease Risk

Broke On: Saturday, 11 November 2023 Wegovy reduced the incidence of heart attack, stroke, or death from heart disease by 20%. Cardiovascular benefits appeared almost immediately after starting treatment. Patients taking the highest dose of Wegovy experienced a drop in blood sugar levels and inflammation. Novo Nordisk plans to seek expanded US approval for Wegovy to reduce the risk of major adverse cardiovascular events.